Praxis Precision Medicines Inc.
Praxis Precision Medicines Receives FDA Breakthrough Therapy Designation for Relurigine
Summary
Praxis Precision Medicines, Inc. announced on July 17, 2025, that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) for relutrigine, a sodium channel functional state modulator, for the treatment of patients with SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA's decision was supported by positive data from the Phase 2 EMBOLD study and an 11-month open-label extension. Additionally, Praxis has initiated the EMERALD study to further evaluate relutrigine in patients with all types of DEEs. The company has also commenced an investor quiet period in anticipation of reporting topline results from the RADIANT Phase 2 study by mid-year 2025.
Profitelligence Alerts
Get alerts for PRAX
Be first to know when Praxis Precision Medicines Inc. files with the SEC.
Filing Categories
Advertisement
About Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
Official SEC Documents
Advertisement